Все публикации

0:21:39

“How I treat” based on the new/updated classification systems

0:24:49

How I treat” a patient with lower-risk MDS showing signs of ESA failure​

0:04:12

What does data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?

0:27:43

Quality of life assessment and transfusion-free survival

0:13:22

How can structural variant assessment assist in MRD assessment in MDS?

0:31:15

The challenges of measuring overall survival in elderly patients with MDS.

0:11:00

How do we differentiate high-risk MDS from AML?

0:08:56

How do we treat high-risk patients outside of a clinical trial?

0:36:27

What factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?

0:08:06

How could venetoclax combinations improve outcome in high-risk MDS?

0:20:33

Sequence of therapy in myelodysplastic syndromes

0:05:39

Highlights of the 8th Translational Research Conference: Myelodysplastic Syndromes

0:11:45

MDS International Guidelines 2022

0:08:38

Hot topics relevant to MDS

0:07:57

What does the FIGARO trial reveal about predictors of outcome post-transplant?

0:13:13

Can IPSS-R be used as a prognostic tool in HSCT in regions where molecular analysis is unavailable?

0:04:59

Do mRNA-based COVID vaccines lead to adverse events in recently transplanted patients?

0:07:17

New clinical advances in MDS risk categorization

0:19:36

How can the hematologic toxicities with Ven+Aza be managed more effectively?

0:07:33

What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be manag...

0:08:40

What new treatments are available for high-risk MDS? What does this mean for patients?

0:04:20

What do the PANTHER trial results tell us about first-line treatment for high-risk MDS?

0:06:14

How successful is CPX-351 as first-line treatment for MDS?

0:06:06

What new developments are there in the treatment of relapsed or refractory MDS?